| Literature DB >> 21855650 |
Jason Mulvenna1, Ponlapat Yonglitthipagon, Banchob Sripa, Paul J Brindley, Alex Loukas, Jeffrey M Bethony.
Abstract
Cholangiocarcinoma (CCA)--bile duct cancer--is associated with late presentation, poses challenges for diagnosis, and has high mortality. These features t highlight the desperate need for biomarkers than can be measured early and in accessible body fluids such as plasma of people at risk for developing this lethal cancer. In this manuscript, we address previous limitations in the discovery stage of biomarker(s) for CCA and indicate how new generation of "omics" technologies could be used for biomarker discovery in Thailand. A key factor in the success of this biomarker program for CCA is the combination of cutting edge technology with strategic sample acquisition by a biorepositories.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21855650 PMCID: PMC3223551 DOI: 10.1016/j.parint.2011.06.005
Source DB: PubMed Journal: Parasitol Int ISSN: 1383-5769 Impact factor: 2.230